{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:28:29Z","timestamp":1790090909584,"version":"4.0.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.vaccine.2025.128124","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:59:36Z","timestamp":1765933176000},"page":"128124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Herpes zoster vaccination among immunocompromised adults in the United States"],"prefix":"10.1016","volume":"72","author":[{"given":"Justin","family":"Carrico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"McGuiness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Stempniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Gatwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.128124_bb0005","unstructured":"Leung J, Harrington T, Dooling K. Epidemiology and Prevention of Vaccine-Preventable Diseases. Chapter 23: Zoster, https:\/\/www.cdc.gov\/pinkbook\/hcp\/table-of-contents\/chapter-23-zoster.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/herpes-zoster.html; 2024 [accessed 1 April 2025]."},{"key":"10.1016\/j.vaccine.2025.128124_bb0010","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12879-015-1262-8","article-title":"Annual incidence rates of herpes zoster among an immunocompetent population in the United States","volume":"15","author":"Johnson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128124_bb0015","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s13555-023-00988-y","article-title":"Burden of herpes zoster among patients with psoriasis in the United States","volume":"13","author":"Singer","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.vaccine.2025.128124_bb0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","article-title":"Incidence of herpes zoster in patients with altered immune function","volume":"42","author":"Chen","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2025.128124_bb0025","series-title":"Presented at AMCP 2024; April 15\u201318, 2024","article-title":"Risk of herpes zoster among adults initiating immunosuppressive therapies in the United States","author":"Gatwood","year":"2024"},{"key":"10.1016\/j.vaccine.2025.128124_bb0030","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.cgh.2017.12.052","article-title":"Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study","volume":"16","author":"Khan","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2025.128124_bb0035","article-title":"Incidence and risk of herpes zoster in patients with ulcerative colitis and Crohn\u2019s disease in the USA","volume":"11","author":"Singer","year":"2023","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"suppl 1","key":"10.1016\/j.vaccine.2025.128124_bb0040","first-page":"50","article-title":"Herpes zoster incidence in patients with multiple sclerosis: A retrospective cohort study","volume":"25","author":"Stempniewicz","year":"2023","journal-title":"Int J MS Care"},{"key":"10.1016\/j.vaccine.2025.128124_bb0045","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/QAI.0b013e318266cd3c","article-title":"Herpes zoster among persons living with HIV in the current antiretroviral therapy era","volume":"61","author":"Blank","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2025.128124_bb0050","unstructured":"Stempniewicz N, Steffens A, Kim K, DuCharme M, Trenz H, Garris CP, Singer D. Herpes Zoster Incidence in People with HIV: A Retrospective Cohort Study [Poster]. ACTHIV, May 4\u20136, 2023, Phoenix, AZ, USA, https:\/\/acthiv.org\/wp-content\/uploads\/2023\/05\/ACTHIV-poster-approval_final.pdf; [accessed 1 April 2025]."},{"key":"10.1016\/j.vaccine.2025.128124_bb0055","first-page":"63","article-title":"Burden of herpes zoster among patients with psoriatic arthritis in the United States","volume":"14","author":"Singer","year":"2024","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.vaccine.2025.128124_bb0060","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/acr.21928","article-title":"Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study","volume":"65","author":"Veetil","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.vaccine.2025.128124_bb0065","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3899\/jrheum.220986","article-title":"Incidence of herpes zoster in patients with rheumatoid arthritis in the United States: a retrospective cohort study","volume":"50","author":"Singer","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.vaccine.2025.128124_bb0070","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1055-9965.EPI-12-0815","article-title":"The epidemiology of herpes zoster in patients with newly diagnosed cancer","volume":"22","author":"Habel","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2025.128124_bb0075","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008746","article-title":"Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: a retrospective cohort study","volume":"96","author":"Mao","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.vaccine.2025.128124_bb0080","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/ciu498","article-title":"Vaccination against zoster remains effective in older adults who later undergo chemotherapy","volume":"59","author":"Tseng","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128124_bb0085","doi-asserted-by":"crossref","unstructured":"Stempniewicz N, Steffens A, Kim K, Jorga A, Bell CF, DuCharme M, Trenz H, Singer D. Herpes zoster incidence in patients with systemic lupus erythematosus: A retrospective cohort study [POS1502], https:\/\/ard.bmj.com\/content\/annrheumdis\/82\/Suppl_1\/1108.2.full.pdf; [accessed 1 April 2025].","DOI":"10.1136\/annrheumdis-2023-eular.3029"},{"key":"10.1016\/j.vaccine.2025.128124_bb0090","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Zoster-039 study g. immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128124_bb0095","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bbmt.2016.12.620","article-title":"Herpes zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies","volume":"23","author":"Sahoo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.vaccine.2025.128124_bb0100","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","article-title":"Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Winston DJ, Mullane KM, Cornely OA, Boeckh MJ, Brown JW, Pergam SA, Trociukas I, Zak P, Craig MD, Papanicolaou GA, Velez JD, Panse J, Hurtado K, Fernsler DA, Stek JE, Pang L, Su SC, Zhao Y, Chan ISF, Kaplan SS, Parrino J, Lee I, Popmihajlov Z, Annunziato PW, Arvin A, Team VPT","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.128124_bb0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.128124_bb0110","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s12325-017-0553-4","article-title":"Duration of antiviral prophylaxis and risk of herpes zoster among patients receiving autologous hematopoietic stem cell transplants: a retrospective, observational study","volume":"34","author":"Zhang","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2025.128124_bb0115","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221091188","article-title":"Comparative risk of herpes zoster in patients with psoriatic disease on systemic treatments: a systematic review and network meta-analysis","volume":"13","author":"Chiu","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.vaccine.2025.128124_bb0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.128124_bb0125","unstructured":"U.S. Food & Drug Administration (FDA). SHINGRIX, https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/shingrix; [accessed 1 April 2025]."},{"key":"10.1016\/j.vaccine.2025.128124_bb0130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.128124_bb0135","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the advisory committee on immunization practices - United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.128124_bb0140","unstructured":"Centers for Disease Control and Prevention (CDC). Clinical considerations for Shingrix use in immunocompromised adults aged \u226519 years, https:\/\/www.cdc.gov\/shingles\/hcp\/vaccine-considerations\/immunocompromised-adults.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/hcp\/immunocompromised-adults.html; [accessed 1 Apr 2025]."},{"key":"10.1016\/j.vaccine.2025.128124_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2025.01.045","article-title":"Effectiveness and safety of the recombinant zoster vaccine in individuals >\/=50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study","author":"Rayens","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.128124_bb0150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial","volume":"70","author":"Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Kim SI, Zaltzman J, Ortiz F, Campistol Plana JM, Fernandez Rodriguez AM, Rebollo Rodrigo H, Campins Marti M, Perez R, Gonzalez Roncero FM, Kumar D, Chiang YJ, Doucette K, Pipeleers L, Aguera Morales ML, Rodriguez-Ferrero ML, Secchi A, McNeil SA, Campora L, Di Paolo E, El Idrissi M, Lopez-Fauqued M, Salaun B, Heineman TC, Oostvogels L, Group ZS","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128124_bb0155","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Zoster-015 HZ\/su study group. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128124_bb0160","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/cncr.31909","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial","volume":"125","author":"Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, Grande E, Marrupe Gonzalez D, Lowndes S, Puente J, Kristeleit H, Farrugia D, McNeil SA, Campora L, Di Paolo E, El Idrissi M, Godeaux O, Lopez-Fauqued M, Salaun B, Heineman TC, Oostvogels L, Zoster-028 Study G","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2025.128124_bb0165","article-title":"Vaccination coverage among adults in the United States","author":"Hung","year":"2022","journal-title":"National Health Interview Survey"},{"key":"10.1016\/j.vaccine.2025.128124_bb0170","first-page":"11;ofae211","article-title":"Incidence of herpes zoster and postherpetic neuralgia and herpes zoster vaccination uptake in a US administrative claims database. Open forum","author":"Marcum","year":"2024","journal-title":"Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128124_bb0175","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/pop.2023.0284","article-title":"Knowledge, attitudes, and practices regarding herpes zoster vaccination among specialists","volume":"27","author":"Singer","year":"2024","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.vaccine.2025.128124_bb0180","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2488093","article-title":"Herpes zoster vaccination: primary care provider knowledge, attitudes, and practices","volume":"21","author":"Stempniewicz","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.128124_bb0185","unstructured":"European Medicines Agency. Zostavax, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zostavax-epar-product-information_en.pdf; [accessed 1 April 2025]."},{"key":"10.1016\/j.vaccine.2025.128124_bb0190","unstructured":"GlaxoSmithKline Biologicals. SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) injectable suspension, for intramuscular use, https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Shingrix\/pdf\/SHINGRIX.PDF; 2025 [accessed July 17, 2025]."},{"key":"10.1016\/j.vaccine.2025.128124_bb0195","doi-asserted-by":"crossref","DOI":"10.1093\/milmed\/usaf009","article-title":"Pneumococcal and herpes zoster vaccination rates among U.S. veterans with chronic inflammatory disease on biologic medications: a quality improvement project","author":"Phomakay","year":"2025","journal-title":"Mil Med"},{"key":"10.1016\/j.vaccine.2025.128124_bb0200","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1080\/21645515.2021.1879579","article-title":"Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019","volume":"17","author":"Patterson","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.128124_bb0205","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.1016\/j.vaccine.2022.10.065","article-title":"Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50-64 years in the United States","volume":"40","author":"Leung","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128124_bb0210","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/j.vaccine.2022.03.006","article-title":"Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017-2021","volume":"40","author":"LaMori","year":"2022","journal-title":"Vaccine"},{"issue":"62","key":"10.1016\/j.vaccine.2025.128124_bb0215","first-page":"526","article-title":"Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: a retrospective pharmacy and medical claims analysis","volume":"2022","author":"Patterson","year":"2003","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.vaccine.2025.128124_bb0220","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/art.42261","article-title":"Recombinant zoster vaccine uptake and risk of flares among older adults with immune-mediated inflammatory diseases in the US","volume":"74","author":"Leung","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.vaccine.2025.128124_bb0225","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.vaccine.2022.10.076","article-title":"Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States","volume":"41","author":"Fix","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128124_bb0230","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1016\/j.vaccine.2023.04.067","article-title":"Recombinant zoster vaccine coverage in the United States: an analysis of claims-based data","volume":"41","author":"Lewis","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128124_bb0235","article-title":"Disparities in recombinant zoster vaccine coverage among adults in the United States by race and ethnicity and social determinants of health [abstract]","volume":"S172","author":"Singer","year":"2023","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.vaccine.2025.128124_bb0240","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.vaccine.2020.12.076","article-title":"Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older","volume":"39","author":"Ackerson","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128124_bb0245","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2334-13-32","article-title":"The disease burden of pertussis in adults 50 years old and older in the United States: a retrospective study","volume":"13","author":"McGuiness","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128124_bb0250","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1080\/13696998.2019.1649267","article-title":"Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data","volume":"22","author":"Liu","year":"2019","journal-title":"J Med Econ"},{"key":"10.1016\/j.vaccine.2025.128124_bb0255","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.yebeh.2015.12.039","article-title":"Changing the approach to treatment choice in epilepsy using big data","volume":"56","author":"Devinsky","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.vaccine.2025.128124_bb0260","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/14760584.2024.2441255","article-title":"Trends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018-2024: a database study","volume":"24","author":"Zheng","year":"2025","journal-title":"Expert Rev Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:59:02Z","timestamp":1768453142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25014227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":52,"alternative-id":["S0264410X25014227"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128124","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Herpes zoster vaccination among immunocompromised adults in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 GSK Plc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128124"}}